

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
21 September 2023 (21.09.2023)



(10) International Publication Number  
**WO 2023/177689 A1**

(51) International Patent Classification:  
**A61K 38/17** (2006.01) **A61P 27/02** (2006.01)

[US/US]; 100 Bayer Boulevard, Whippany, New Jersey 07981 (US).

(21) International Application Number:  
PCT/US2023/015223

(72) Inventors: **VITTI, Robert L.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BERLINER, Alyson J.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **CHU, Karen**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ASMUS, Friedrich**; Eitel-Fritz-Str. 2, 14129 Berlin (DE). **DA SILVA LEAL, Sergio Casimiro**; In den Steinreben 6A, 4153 Reinach (CH). **EISSING, Thomas**; Kirschbaum 15, 40764 Langenfeld (DE). **RITTENHOUSE, Kay D.**; 15 Ridgewood Drive, Randolph, New Jersey 07869 (US).

(22) International Filing Date:  
14 March 2023 (14.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/319,865 15 March 2022 (15.03.2022) US  
63/404,511 07 September 2022 (07.09.2022) US  
63/404,889 08 September 2022 (08.09.2022) US  
63/411,589 29 September 2022 (29.09.2022) US  
63/412,158 30 September 2022 (30.09.2022) US  
63/421,296 01 November 2022 (01.11.2022) US  
63/434,918 22 December 2022 (22.12.2022) US  
63/444,470 09 February 2023 (09.02.2023) US  
3190726 22 February 2023 (22.02.2023) CA  
63/447,577 22 February 2023 (22.02.2023) US

(74) Agent: **TERMES, Lance A.**; Schwabe, Williamson & Wyatt PC, 1211 SW 5th Ave., Suite 1900, Portland, Oregon 97204 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BAYER HEALTHCARE LLC**

(54) Title: EXTENDED, HIGH DOSE VEGF ANTAGONIST REGIMENS FOR TREATMENT OF ANGIOGENIC EYE DISORDERS




FIG. 1

(57) Abstract: The present invention relates to regimens for the treatment of angiogenic eye disorders such as DR and DME characterized by high doses of aflibercept and lengthening intervals between doses.

[Continued on next page]

WO 2023/177689 A1

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*